Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.

Blood - 1 May 2007

Kuptsova Nataliya, Kopecky Kenneth J, Godwin John, Anderson Jeanne, Hoque Ashraful, Willman Cheryl L, Slovak Marilyn L, Ambrosone Christine B

Abstract excerpt

Repair of damage to DNA resulting from chemotherapy may influence drug toxicity and survival in response to treatment. We evaluated the role of polymorphisms in DNA repair genes APE1, XRCC1, ERCC1, XPD, and XRCC3 in predicting therapeutic outcomes of older adults with acute myeloid leukemia (AML) from 2 Southwest Oncology Group (SWOG) clinical trials. All patients received standard chemotherapy induction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Haplotypes

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Proteins

Share to Predictive Value of Tests

Share to Proportional Hazards Models

Share to Treatment Outcome

Source

Identifiers

PMID: 17197435
DOI: 10.1182/blood-2006-05-022111

Genes

ERCC1
XRCC3
XRCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials.PMID 17197435Read ↗

Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia.Semantic proximity Read ↗

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.Semantic proximity Read ↗

Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.Semantic proximity Read ↗

Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia.Semantic proximity Read ↗

Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.Semantic proximity Read ↗

DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.Semantic proximity Read ↗

XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients.Semantic proximity Read ↗

Polymorphisms in XPC provide prognostic information in acute myeloid leukemia.Semantic proximity Read ↗

Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.Semantic proximity Read ↗

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia.Semantic proximity Read ↗

Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.